Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report

Sickle cell disease (SCD) is one of the most common hematological diseases, which results in variable complications. The treatment of SCD is evolving but limited options are available for now. Acute chest syndrome (ACS) is one of the serious complications observed in SCD and a challenging one in pre...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2023-12, Vol.28 (1), p.2229115-2229115
Main Authors: Afana, Mohammad S, Abu-Tineh, Mohammad, Alshurafa, Awni, Yasin, Ahmed K, Ahmed, Khalid, Abdulgayoom, Mohammed, Yassin, Mohamed A
Format: Article
Language:English
Subjects:
acute chest syndrome
Crizanlizumab
hemoglobinopathies
Hydroxyurea
sickle cell disease
vaso-occlusive crisis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sickle cell disease (SCD) is one of the most common hematological diseases, which results in variable complications. The treatment of SCD is evolving but limited options are available for now. Acute chest syndrome (ACS) is one of the serious complications observed in SCD and a challenging one in prevention. Crizanlizumab is a monoclonal antibody that binds to P-selectin and improves blood flow by preventing sickle cell adhesion to endothelium, resulting in improvement of vaso-oclusive crises (VOC). It is not well evaluated in terms of ACS prevention. Here we report a 23-year-old patient with SCD and recurrent ACS; she was started on Crizanlizumab and she had no more ACS, but once she was off Crizanlizumab she developed ACS again, later Crizanlizumab was re-started, and the patient has improved significantly.
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2023.2229115